NDAOPHTHALMICSOLUTION/DROPS1 Generic Approved
Approved
Feb 2012
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
6/8 — Strong
ZIOPTAN (tafluprost) by Thea Pharma is prostaglandin receptor agonists [moa]. Approved for prostaglandin analog [epc]. First approved in 2012.
Drug data last refreshed 48m ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZIOPTAN is a prostaglandin analog ophthalmic solution approved in 2012 for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It works by binding to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor. The product is administered as daily eye drops.
$0.002BPart D
LOE ApproachingDeclining
2.7 years to LOEDeclining spending and LOE within 2.7 years suggest shrinking brand team and transition to generic support roles.
Mechanism of Action
Prostaglandin Receptor Agonists
Pharmacologic Class:
Prostaglandin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (16)
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
Started Sep 2021
50 enrolled
Ocular Surface DiseasePrimary Open Angle Glaucoma
Prospective, Single Center Switching Study of 0.0015% Tafluprost Ophthalmic Solution in Primary Open-angle Glaucoma and Ocular Hypertension Patients With Corneal Disorders (Switching From 0.005% Latanoprost Ophthalmic Solution)
Started Apr 2018
1 enrolled
Glaucoma, Primary Open Angle
Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing
Started Jan 2017
42 enrolled
Glaucoma, Open-Angle
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
Started Sep 2015
67 enrolled
Ocular HypertensionGlaucoma
A Study to Evaluate Pharmacokinetics of Tafluprost Ophthalmic Solution (0.0015%) in Pediatric Patients With Glaucoma or Ocular Hypertension
Started Jun 2014
17 enrolled
GlaucomaOcular Hypertension
Worked on ZIOPTAN at Thea Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.